BNO 5.26% 20.0¢ bionomics limited

BNC210 coverage on Channel 9, page-25

  1. 593 Posts.
    lightbulb Created with Sketch. 24
    I think there are a number of matters to consider when it comes to BNO. DDD makes the point very well. There are, of course, a couple of shots on goal. The 'biggest" (if that is the right term) is the result with 210 in the PTSD study. Yes, we are all holding on waiting for this. The reality is that there is other stuff going on. But, will it ever see the light of day? The answer to that may depend on the clinical trial results and an asset sale.

    On the other hand, the selling down of the stock (which has to end eventually) is keeping this from climbing (even if the climb would be slow). That may be the thing that requires the most patience. GLTA
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.